Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

Recruiting now · Phase 1

Conditions studied: Moderate Renal Impairment

In brief

This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.

Key facts

Study ID

NCT07227922

Run by

Sparrow Pharmaceuticals

People needed

16

Starts

2025-11-30

Expected to finish

2026-07-01

Last updated by the study team

2025-12-23

Who can join

Age: 18 and older, up to 83. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female participants with stable moderate renal impairment (estimated glomerular filtration rate [eGFR]: 30 to <60 mL/min) and matched (by sex, age, and weight) control participants with normal renal function (eGFR: ≥90 mL/min) will be enrolled in this trial.

You may not qualify if…

• Participant whose current or recent medical conditions, medications, or procedures could increase participant's safety risk, or whom the Investigator considers not suitable for entry into the trial or the participant, or who has clinically significant abnormal 12-lead electrocardiogram (ECG)/ vital sign measurements/ laboratory test results at Screening and Check-in, will not be enrolled

Where it is running

• Orlando Clinical Research Center — Orlando, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.